A Vaccine to Prevent Leishmaniasis
Technical Report,15 Sep 2017,14 Sep 2018
BAYLOR COLL OF MEDICINE HOUSTON TX HOUSTON United States
Pagination or Media Count:
Building on extensive preliminary data and an established consortium of academic, government, military, and product development partners, we propose to develop a production process for a novel, bivalent vaccine against leishmaniasis, a serious neglected tropical disease NTD of military and civilian personnel now spreading rapidly in conflict zones of the Middle East and Central Asia. The proposed Cutaneous Leishmania Vaccine CL-Vax is a bivalent, recombinant protein-based vaccine that will be comprised of a specific Leishmania parasite antigen together with a novel sand fly salivary antigen, co-administered at bedside with an adequate adjuvant. The components of the vaccine will be extensively characterized, and their immunogenicity and efficacy will be confirmed in animal models.
- Medicine and Medical Research